top of page
Search

Jext (adrenaline (epinephrine) acid tartrate) Adrenaline Auto-Injector Now PBS Listed and Available in Australia  

Biocelect Pty Ltd today announced the Australian launch of Jext, a new adrenaline autoinjector now listed on the Pharmaceutical Benefits Scheme (PBS) and available nationally, supporting subsidised access for eligible patients for the emergency treatment of anaphylaxis (1-2).

  

The introduction of Jext adds an additional PBS listed adrenaline autoinjector option to the established anaphylaxis treatment landscape in Australia, providing healthcare professionals and pharmacists with greater choice when supporting patients at risk of severe allergic reactions.  

Jext is a pre-filled autoinjector designed for easy use and is available in two strengths (150 micrograms and 300 micrograms) to support weight-based prescribing (1).


See more in the full media release document below

References:  

1. Jext® 300 & Jext® Jnr 150 (adrenaline (epinephrine) acid tartrate) Australian Product Information. 2026  

 
 
Biocelect Logo_Colour.png

© 2026 Biocelect

Product, Medical & Patient Enquiries -  Phone: +61 1300 848 628 Email: patientsafety@biocelect.com

General Enquiries & Ordering Information - Phone: +61 1300 907 411 Email: info@biocelect.com

All phone numbers are free call from Australia & New Zealand 

Australian Office: Level 4, 143 Macquarie Street, Sydney NSW 2000, Australia

Registered Office Australia: Level 29, 66 Goulburn Street, Sydney NSW 2000, Australia

Registered Office New Zealand: Level 5, Wynn Williams House, 47 Hereford Street, Christchurch 8013, New Zealand

Biocelect acknowledges the Traditional Custodians of Australia and their continued connection to land,
sea and community. We pay our respects to the Elders, emerging, past and present. 

Privacy Policy

Last Updated 2nd June 2026

  • linkedin
bottom of page